Theolytics
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
Total raised
€5.5M
€5,542,238
Funding rounds
2
Investors
3
distinct backers
Active since
2021-01
latest 2021-07
Funding by year
EUR raised per yearSignals
Medium confidenceRaise-next likelihood16
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Exit likelihood13
base rate 12% (2+ rounds)
- ▲ 9y since founding
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-07-15 | Series A | — | M Ventures | View deal → |
| 2021-01-07 | Series A | €5.5M | Epidarex Capital,Taiho Ventures | View deal → |
Investors
3Related news
- Theolytics Expands Series A Funding Roundfinsmes.com · 2021-07
- finsmes.com